MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Exact Sciences posts Q4 revenue gains, narrows losses

Exact Sciences posts Q4 revenue gains, narrows losses

By

Exact Sciences Corp. (NSDQ:EXAS) posted fourth-quarter sales of $1.2 million for the three months ended Dec. 31, 2009, compared with negative revenues of $109,000 during the same period in 2008. Net losses narrowed 13.9 percent to $1.8 million, compared with $2.1 million during Q4 2008:

Press Release

Exact Sciences Reports Fourth-Quarter, Full-Year 2009 Financial
Results

MADISON, Wis.–(BUSINESS WIRE)–Exact
Sciences Corp. (Nasdaq: EXAS) today announced its financial results
for the fourth quarter ended Dec. 31, 2009.

Exact reported total revenues of $1.2 million for the fourth quarter of
2009, compared to total revenues of ($109,000) during the same period of
2008. Fourth-quarter 2009 total revenues increased due to the quarterly
non-cash allocation that resulted from a 2009 intellectual property
license transaction. Total revenues for the year ended Dec. 31, 2009,
were $4.8 million, compared to total revenues of ($867,000) for the
prior year.

Exact reported a net loss of ($1.8) million, or ($0.05) a share, for the
fourth quarter of 2009. The company had a net loss of ($2.1) million, or
($0.08) a share, for the same period of 2008. Exact’s net loss for the
year ended Dec. 31, 2009, was ($9.1) million, or ($0.28) a share,
compared to ($9.7) million, or ($0.36) a share, for the prior year.

Operating expenses for the fourth quarter of 2009 were $3.0 million,
compared to $2.0 million for the same period of 2008. Operating expenses
for the year ended Dec. 31, 2009, were $13.9 million, compared to $9.1
million for the same period of 2008.

Exact ended the fourth quarter of 2009 with cash, cash equivalents and
marketable securities of $24.3 million, compared to $4.9 million at Dec.
31, 2008.

“After joining the company last April, the company’s new management
outlined three key priorities for 2009: product development, clinical
trial planning and creating a performance culture. We are pleased with
the great progress we made on each of those priorities,” said Kevin T.
Conroy, the company’s president and chief executive. “We simplified our
sDNA test and strengthened its detection capability by licensing
Hologic’s qInvader chemistry. We made significant strides in our
clinical trial planning, engaging the FDA and others in our trial
design, and initiating the recruitment of top-tier investigators. We
rebuilt our research and development team, improved our intellectual
property portfolio and strengthened our balance sheet.

“The licensing and collaboration relationship we entered with Mayo
Clinic at mid-year was an important part of the product development
progress we made during 2009,” Mr. Conroy said. “The broad research and
development collaboration with Dr. David Ahlquist and his lab is a
critical part of our ongoing product refinement efforts.”

Keywords: Exact Sciences, EXAS, fourth quarter, Q4, sales, net losses, earnings

Meta: Exact Sciences Reports Fourth-Quarter, Full-Year 2009 Financial
Results

In case you missed it

RSS From Medical Design & Outsourcing

  • Bringing motion to medicine: How Actuated Medical is innovating deep brain stimulation and more
    Actuated Medical is making electrode placement for deep brain stimulation easier and less traumatic. Nearly 16 years ago, Actuated Medical co-founder, President and CEO Maureen Mulvihill was working for a company making actuators that were the size of a grain of rice. While the company was focused on components, she wanted to help patients more.… […]
  • Elkem Silicones opens new medical silicone production facility
    Elkem Silicones announced today that it opened its new specialized facility for producing high-purity medical silicones. York, South Carolina-based Elkem held a grand opening on Sept. 28. Customers and local, state and federal officials attended the event, which featured a ribbon-cutting ceremony, facility tours and a reception. “Elkem’s investment in this highly specialized facility demonstrates… […]
  • Three considerations for reshoring your medical device components and assemblies
    Reshoring medical devices — moving production back to the United States — requires strategic and complex navigation. John Banks and Richard Landry, Beacon MedTech Solutions Reshoring is a topic of conversation with almost every biopharma, life sciences and medical company currently outsourcing production of thermoplastic or silicone parts, products and assemblies to overseas molders. Just… […]
  • How Medline maintains quality while innovating and growing
    Medline President of Quality and Regulatory Affairs Lara Simmons offers insight into innovation and quality as the company grows. When Lara Simmons joined Medline Industries in 1991, she began by performing packaging validations. At the time, Medline was bringing in $250 million in sales per year, and the company’s quality assurance team had only about… […]
  • How this inside-out vascular access system simplifies catheter placement
    Bluegrass Vascular Technologies is making catheter placement procedures for dialysis and chemotherapy easier and safer using inside-out technology, explains CEO and President Gabi Niederauer. Bluegrass Vascular Technologies has figured out a way to make a catheter sheath go inside the body and back out for easy catheter placement in standard access procedures. The San Antonio,… […]
  • 6 Steps for Winning at Life Sciences Bid Management
    By Bob Steller, Industry Principal – Life Sciences Discover the secret to success for planning, executing—and winning—profitable bids Did you know that 85% of revenue in the medical technology market comes through bids and tenders? For Life Sciences companies like yours, one key to building and expanding your business is mastering the art and science… […]
  • Digital Pump Customization: Unlocking the True Potential of BLDC Motors
    By using advanced electric motors, a variety of motor and pump parameters can be customized to individual customer needs. It is becoming increasingly more valuable to be able to monitor all electronic components on board medical devices. By taking advantage of the full capabilities and digital customization of brushless direct current (BLDC) motor controllers, pumps… […]
  • Why Automate? Justification and Impact Explained
    Do you want to integrate automation into your manufacturing process but you’re unsure where to start? Maybe your biggest hurdle is justifying the costs associated with the change. Effectively communicating the reasons why and the ROI to all stakeholders in this major shift is a necessary starting point. Justifying the Need to Automate Increased production… […]
  • In vivo electroporation is an engineering solution for drug and gene delivery
    Why the new buzz about an old technique? Harness the potential of an existing technology for modern medicine. Daniel Friedrichs, Minnetronix Medical Reversible electroporation is the use of an electric field to open pores in a cell wall, allowing transport of drugs, DNA or other “cargo” into a cell — in particular, allowing delivery of… […]
  • FDA and VA Ventures Innovation Institute partner on new medical device testing tools
    The Department of Veterans Affairs’ VA Ventures Innovation Institute in Seattle will host up to a dozen FDA staffers in a new collaboration to develop and share new tools for medical device testing safety and efficacy. The agencies intend to provide developers of devices and new technology with off-the-shelf tools that can help streamline regulatory… […]
  • How Boston Scientific is managing labor shortages with cobots and Spanish
    Boston Scientific (NYSE: BSX) executives said two labor-shortage strategies are paying off in a big way for the medical device maker, which has around 41,000 employees across the globe. Collaborative robotics and Spanish-speaking shifts are helping Boston Scientific deal with labor shortages in the U.S. and elsewhere. That’s according to Global Operations EVP Brad Sorenson… […]

Leave a Reply